Compare CBNK & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBNK | AURA |
|---|---|---|
| Founded | 1974 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 440.4M | 377.2M |
| IPO Year | 2018 | 2021 |
| Metric | CBNK | AURA |
|---|---|---|
| Price | $29.38 | $6.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $34.50 | $20.20 |
| AVG Volume (30 Days) | 34.7K | ★ 229.4K |
| Earning Date | 04-27-2026 | 03-20-2026 |
| Dividend Yield | ★ 1.67% | N/A |
| EPS Growth | ★ 60.85 | 9.33 |
| EPS | ★ 3.41 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.20 | N/A |
| Revenue Next Year | $8.52 | N/A |
| P/E Ratio | $8.43 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.69 | $4.73 |
| 52 Week High | $36.40 | $7.48 |
| Indicator | CBNK | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 53.58 | 63.58 |
| Support Level | $27.55 | $5.83 |
| Resistance Level | $33.33 | $6.67 |
| Average True Range (ATR) | 0.93 | 0.40 |
| MACD | 0.04 | 0.07 |
| Stochastic Oscillator | 68.35 | 75.72 |
Capital Bancorp Inc is a bank holding company. The company through its holdings operates as a commercial-focused community bank that serves businesses, not-for-profit associations, and entrepreneurs throughout the region. The bank operates through four divisions including Commercial Banking, Capital Bank Home Loans, OpenSky, and Windsor Advantage, and also operates in five business segments: commercial banking; mortgage banking; credit cards; government loan servicing; and corporate activities.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.